DEFB126

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DEFB126 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB126 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher DEFB126 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB126 expression acts as an unfavorable survival marker.

SCLC are the cancer types where DEFB126 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SCLCOSMedianII,III,IV0.1920.699.00218view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

DEFB126–SCLC (OS)

Kaplan–Meier survival curve for DEFB126 mutant vs wild-type samples in SCLC.

Open the SCLC breakdown →

Exploration